Pinnacle Medicines raised an $89 million Series B to accelerate development of its oral peptide programs, bringing total disclosed funding to $134 million. The round was co-led by LAV and Foresite Capital, with participation from Quant Capital, Hankang Capital, RA Capital Management, Logos Capital, Orbimed, and others. The financing targets translation of peptide therapeutics into stable, scalable oral drug formats.